Compare iShares Global Tech ETF (IXN) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Tech ETF vs TG Therapeutics Inc — how do they compare? iShares Global Tech ETF trades at $149.84 (market cap $10.03B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: iShares Global Tech ETF is the larger of the two by market cap, and iShares Global Tech ETF is more actively traded (286,617 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Tech ETF for 47 Days and TG Therapeutics Inc for 16 Days on average.
| IXN | TGTX | |
|---|---|---|
Market Cap | $10.03B | $8.16B |
Volume | 286,617 | 1,735,121 |
Sector | Sector/Thematic | Health |
52-Week High | $152.94 | $59.06 |
52-Week Low | $95.76 | $26.94 |
Typical Hold Time | 47 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IXN, the iShares Global Tech ETF, trades at $149.84, down 1.52% on the day but near its 52-week high of $151.40, indicating strong momentum. Technical signals are bullish overall, with moving averages supporting an uptrend, while oscillators remain neutral. Recent news highlights the ETF hitting new highs and trading at a high-teens P/E with a compelling long-term EPS growth outlook, though concentration and AI exposure pose risks.
The outlook for IXN is positive, driven by global tech diversification and AI growth opportunities, but investors face risks from portfolio concentration and market volatility. Wall Street sentiment is bullish, with analysts citing valuation compression and earnings potential as key catalysts for further gains.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares Global Tech ETF
IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
